Abstract: The object of the present invention is a composition of bacterial strains which may comprise Stenotrophomonas sp. strain 2L, Stenotrophomonas sp. strain 5L, Stenotrophomonas sp. strain 6L, Stenotrophomonas sp. strain 3N, Achromobacter sp. strain 4P, Arthrobacter sp. strain 1N, Brevundimonas sp. strain 2N, Brevundimonas sp. strain 5N, Brevundimonas sp. strain 6N, Pseudomonas sp. strain 3G, and Pseudomonas sp. strain 4, deposited under the number KKP 2041p (IAFB Collection of Industrial Microorganisms—Institute of Agricultural and Food Biotechnology in Warsaw), a bioremediation vaccine (bioremediation mixture) which may comprise the composition of these strains, the use of the vaccine in the removal of contaminants from the soil, and the method for the treatment of contaminated soil.

Abstract: The invention refers to a chamber for measurements of electrical properties of reactive powder or liquid samples, allowing the measurement of various electrical parameters to be carried out. The present invention provides the chamber in two variants of embodiment: the multiple use chamber and the single use chamber. The construction of the chamber provides the possibility of carrying out the measurements with the sample placed directly between parallel active surfaces of the electrodes placed coaxially and sliding in a precise manner in to a thin-walled cylinder made of insulating material providing electric insulation. Elements remaining in contact with the sample are made of chemically inert materials. Additionally, a module containing a pair of the electrodes and the cylinder made of insulating material is detachable from the rest of device elements, that enables its loading and hermetic closure in a glovebox filled with inert gas.

Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.

Abstract: The object of the present invention is a composition of bacterial strains which may comprise Stenotrophomonas sp. strain 2L, Stenotrophomonas sp. strain 5L, Stenotrophomonas sp. strain 6L, Stenotrophomonas sp. strain 3N, Achromobacter sp. strain 4P, Arthrobacter sp. strain 1N, Brevundimonas sp. strain 2N, Brevundimonas sp. strain 5N, Brevundimonas sp. strain 6N, Pseudomonas sp. strain 3G, and Pseudomonas sp. strain 4, deposited under the number KKP 2041p (IAFB Collection of Industrial Microorganisms—Institute of Agricultural and Food Biotechnology in Warsaw), a bioremediation vaccine (bioremediation mixture) which may comprise the composition of these strains, the use of the vaccine in the removal of contaminants from the soil, and the method for the treatment of contaminated soil.

Abstract: A medical application of N-oleoyl-dopamine and 3?-O-methyl-N-oleoyl-dopamine for the production of a medication for treatment or prophylaxis of disturbances or states due to deficiency of dopamine, preferably chosen from the group covering oxygen deficiencies (hypoxia) in anesthetized and awake mammals, breathing with atmospheric oxygen (normoxia), for the respiratory responses to hypoxia in mammals, lack of dopamine binding to the membrane system in the mammalian brain, disturbances in metabolic pathways of dopamine metabolism, states of dopamine deficiencies provoked by morbid or genetic factors as well as under condition connected to the physiological process of aging of the organism, through the systemic introduction of the compound to the mammalian organism. A method of production of 3?-O-methyl-N-oleoyl-dopamine in vitro is also disclosed.

Abstract: The invention relates to novel hybrid cholinesterase inhibitors containing the melatonin or its oxidation products unit and tetrahydroacridine unit linked via a carbamate bond. Due to the high selectivity of action, which is expressed with high ratio of IC50 for acetylcholinesterase inhibition to IC50 for butyrylcholinesterase inhibition ([IC50(AChE)]/[IC50(BChE)]), the novel compounds may be used in relief and/or treatment of the neurodegenerative diseases, among them the Alzheimer's disease.

Abstract: A medical application of N-oleoyl-dopamine and 3?-O-methyl-N-oleoyl-dopamine for the production of a medication for treatment or prophylaxis of disturbances or states due to deficiency of dopamine, preferably chosen from the group covering oxygen deficiencies (hypoxia) in anesthetized and awake mammals, breathing with atmospheric oxygen (normoxia), for the respiratory responses to hypoxia in mammals, lack of dopamine binding to the membrane system in the mammalian brain, disturbances in metabolic pathways of dopamine metabolism, states of dopamine deficiencies provoked by morbid or genetic factors as well as under condition connected to the physiological process of aging of the organism, through the systemic introduction of the compound to the mammalian organism. A method of production of 3?-O-methyl-N-oleoyl-dopamine in vitro is also disclosed.

Abstract: The object of the invention is a method for preparing a compound of formula I ##STR1## wherein Me.sup.m+ is a lanthanide and n is a number from 1-3, is used for diagnosis of neoplasms. The compound is prepared by adding an aqueous solution of hydrazide hydrochloride to potassium hexachloroplatinate, the suspension is mixed about two hours at 50.degree. to 60.degree. C. then about 30 minutes at 80.degree. to 90.degree. C., and upon cooling the reaction mixture, the unreacted potassium hexachloroplatinate is separated, the solution is decanted and filtered, and the pH of the filtrate is brought to 3 to 5. Methionine is then added in a molar ratio of methionine to tetrachloroplatinate of 2:1-4:1 and upon careful mixing for about 30 minutes a metal salt is added and preferably ytterbium chloride, and tagged with Yb.sup.-169. The components are then mixed and the pH of the solution is brought to 4-6.5 and filtered through a sterile filter.

Abstract: The subject of the invention is a device synchronizing modes of the laser, fastened in its resonance cavity, in a housing 1 having its inner temperature stabilized, which contains an acousto-optical modulator whose buffer 5, functioning at the same time as a prism, together with a transducer 13 generating an acoustic wave for modulation of a light wave and with a back mirror 11 form an integrated optical element in the form of a prism with a trapezoid base.

Abstract: The invention relates to a method for the preparation of a scintillographic agent which comprises preparing a derivative of iminodiacetic acid particularly an .omega.-chlor-2,4-dimethylacetanilide derivative, and chelating such derivative with a radiometal. The scintillographic agent is adapted for intravenous administration in medical diagnostics, in particular for the diagnosis of the bile canal.

Abstract: The invention relates to a generator of the harmonic of laser light destined in particular for application in the equipment for spectrometric measurements carried out with the laser technique. The substance of the invention is to shorten many times the optic route in the generator of the harmonic of laser light by the replacement of the system of elements of a zero dispersion by at least one dispersive element of a great dispersion, in particular by a rutile prism, combined with the system reversing the polarization surface by 90.degree., in partricular with a 90.degree. polarization rotator or a half-wave plate.